The multifunctional enzyme transglutaminase 2 (TG2) is the target of autoantibodies in the gluten-sensitive enteropathy celiac disease. In addition, the enzyme is responsible for deamidation of gluten peptides, which are subsequently targeted by T cells. In order to understand the regulation of TG2 activity as well as the enzyme's role as an autoantigen in celiac disease, we have addressed structural properties of TG2 in solution using hydrogen/deuterium exchange monitored by mass spectrometry. We demonstrate that Ca 2+ binding, which is necessary for TG2 activity, induces structural changes in the catalytic core domain of the enzyme. Cysteine oxidation was found to abolish these changes, suggesting a mechanism whereby disulfide bond formation inactivates the enzyme. Further, by using TG2-specific human monoclonal antibodies generated from intestinal plasma cells of celiac disease patients, we observed that binding of TG2 by autoantibodies can induce structural changes that could be relevant for the pathogenesis. Detailed mapping of two of the main epitopes targeted by celiac disease autoantibodies revealed that they are located adjacent to each other in the N-terminal part of the TG2 molecule.
SIGNIFICANCE STATEMENT
The enzyme transglutaminase 2 (TG2) is the target of autoantibodies characteristic of the gluten-sensitive enteropathy celiac disease, and intact enzyme activity seems to be required for the disease-causing immune response. TG2 activity is regulated through conformational changes. Ca 2+ binding is required for enzyme activity, whereas oxidation inactivates the enzyme. Using hydrogen/deuterium exchange monitored by mass spectrometry, we have studied differences between active and inactive forms of TG2 in solution and found that oxidation prevents Ca Alternatively, a small-molecule primary amine or water can substitute for lysine in the reaction. When water is used as a substrate, glutamine is converted into glutamic acid, and the reaction is termed deamidation. Gluten peptides are rich in glutamine residues that can be targeted by TG2, and TG2-mediated gluten deamidation plays a central role in the activation of gluten-reactive T cells in celiac disease (4) . Thus, knowing how TG2 activity is regulated is key to our understanding of the initiation of the immune response.
TG2 is ubiquitously expressed and is produced in the cytosol of human cells. A substantial amount of the enzyme, however, is exported to the extracellular environment through an unconventional mechanism (5) . Once outside the cell, TG2 is in a Ca 2+ -rich environment supportive of transamidation/deamidation, and the extracellular enzyme is believed to be involved in crosslinking of matrix proteins (6, 7) . In the cytosol, on the other hand, TG2 presumably works as GTPase (8) . Binding of GTP/GDP inhibits transamidation/deamidation (9, 10) . Thus, a high intracellular concentration of GTP in combination with a low Ca 2+ concentration prevents transglutaminase activity in the cytosol under normal physiological conditions (10, 11) .
Depending on the binding of effectors, TG2 can adopt two distinct conformations (10, 12, 13) . Crystal structures of the enzyme in a complex with GDP or GTP reveal a "closed" conformation, in which the two C-terminal -barrel domains are folded in on the catalytic core domain and cover the active site (14, 15) . Conversely, when a peptide inhibitor was irreversibly attached to the active site cysteine, the enzyme adopted an "open" conformation, where the four structural domains were aligned to give an extended structure (16) . The closed and open conformations are thought to reflect intra-and extracellular TG2, respectively.
Crystallization of TG2 demonstrated that the open conformation can form a vicinal disulfide bond (16) , which has been shown to inactivate the enzyme and presumably serves as a redox switch regulating the activity in the extracellular environment (17, 18) . In its active state, TG2 binds up to six Ca 2+ ions (10, 19) . The open conformation, however, was crystallized without bound Ca 2+ and, hence, does not likely reflect the true structure of the catalytically active enzyme.
Hydrogen/deuterium exchange monitored by mass spectrometry (HDX-MS) has proven to be a valuable tool for studying both dynamic changes in protein conformation and proteinprotein interactions (20) . The method utilizes the exchange of backbone amide hydrogens with deuterium when proteins are placed in a D2O solution. Backbone amide hydrogens engaged in stable hydrogen bonds are protected against exchange with the solvent (21) .
According to the thermodynamic principle, all protecting hydrogen bonds will eventually break as the protein cycles through partially unfolded states. Therefore, over time, all backbone amides become transiently exposed to the solvent and exchange-competent. In this way, the deuterium uptake kinetics directly reflects the backbone dynamics of the protein structure. For a protein-protein complex, the binding interface will usually exhibit a decreased deuterium uptake due to having reduced backbone dynamics and being shielded from the solvent (22) .
Here, we describe the use of HDX-MS to map conformational changes in TG2 induced by Ca 2+ and GTP, and we address the structural implications of cysteine oxidation. By using a panel of TG2-specific monoclonal antibodies (mAbs) (23), we have also mapped the main epitopes targeted by celiac disease autoantibodies. Their locations might explain why one epitope seems to be favored in the response and indicate what drives the activation of autoreactive B cells in celiac disease.
RESULTS

Ca
2+
ions stabilize the structure of TG2 Due to the large difference in hydrodynamic radius between open and closed TG2, the two conformational states can be separated by non-denaturing PAGE (12, 24) . In agreement with earlier reports, we observed that TG2, produced recombinantly in Sf9 insect cells, adopts a closed conformation in the presence of GTP, whereas Ca 2+ in combination with a specific active-site inhibitor induces an open conformation (Fig. 1A) . If no effectors were added to the solutions, the protein was found to populate both conformational states, with the majority of TG2 molecules existing in the open form. Although it is possible that purified TG2 can be associated with effectors derived from the expression system, we will refer to the protein with no added effectors as "effector-free" in the following. Distinct conformational states were also observed when analyzing the intact, deuterated proteins using MS (Fig. 1B and Table S1 ).
When labeling TG2 in the presence of GTP or inhibitor-bound TG2 (iTG2) in the presence of Ca 2+ , we observed a single isotopic distribution in each mass spectrum, indicating that the proteins only populated one conformational state in solution. In the absence of externally added effectors, TG2 gave rise to two isotopic distributions when analyzed by HDX-MS, indicating that the protein adopted two states with different dynamics. The state with the lower deuterium uptake, State A, was found to mimic the GTP-bound state. However, the state displaying a greater deuterium uptake, State B, did not match the deuterium uptake kinetics of Ca 
Binding of Ca
2+
or GTP stabilizes distinct regions in TG2
To locate regions in TG2 which were impacted by effector binding, we compared the deuterium incorporation at the peptide level (local-exchange analysis) in the effector-free protein and in the Ca 2+ -bound and GTP-bound forms. For this purpose, the labeled protein was digested with pepsin prior to MS analysis, resulting in 70.3% sequence coverage. A complete list of identified peptides can be found in Table S2 , and deuterium uptake plots for the N-terminal, core and C-terminal domains are shown in Figure S2 .
Many of the peptides obtained from the catalytic core domain of TG2 incorporated more deuterium and thus appeared more dynamic in the effector-free state than in either of the effector-bound states. This indicates that both Ca and GTP-bound TG2, we observed that the GTP-bound state exhibited less dynamic behavior in the C-terminal domains and regions of the core domain which, according to the reported crystal structures, are involved in inter-domain interactions when the enzyme adopts its closed conformation ( Fig. 2A and Table S2 ). Other parts of the core domain, however, appeared to have a less dynamic structure in the Ca Disulfide bond formation in iTG2 prevents the stabilizing effects of Ca
Cysteine oxidation inactivates TG2 (17, 27, 28) , and intramolecular disulfide bond formation presumably leads to TG2 inactivation in the extracellular environment (18, 29) . In order to study the structural properties of oxidized TG2, we also performed local-exchange analysis on iTG2, which had been incubated with oxidized glutathione prior to the addition of Ca
. The peptides 354-369, 355-369 and 370-378 could no longer be observed after oxidation (Table   S2 ), indicating that Cys370 was engaged in disulfide bond formation, which prevented enzymatic cleavage of the peptide bond between residues 369 and 370. Similarly, the peptides 511-532, 517-532 and 548-555 were found to be sensitive to oxidation, strongly indicating that a bond between Cys524 and Cys554, which are in close proximity according to the crystal structures, had also formed. Local-exchange analysis revealed that oxidized iTG2 exhibited an increased deuterium uptake, compared to Ca 2+ -bound iTG2, in peptides covering the core domain ( Fig. 2B and Table S2 ). Interestingly, within the region 167-354, comprising most of the core domain, oxidized iTG2 instead matched the behavior of the effector-free protein (Table S2) . Thus, even in the presence of Ca 2+ , oxidized iTG2 had a core domain structure resembling that of the effector-free protein.
The N-terminal domain of TG2 is unaffected by effector binding and oxidation state
While changes in the deuterium uptake could be observed in the C-terminal -barrel domains as well as the catalytic core domain, when TG2 was exposed to different effectors, the peptides derived from the N-terminal -sandwich domain exhibited deuteration patterns, which were almost identical under all the investigated conditions, including the oxidized state (Fig 2B and Table S2) 
Binding of autoantibodies can induce structural changes in TG2
The panel of TG2-specific mAbs described above was generated from small intestinal biopsies of celiac disease patients (23) . Based on competitive ELISA experiments, we recently showed that 49 out of 57 mAbs could be placed into one of four distinct epitope groups (epitope 1-4, targeted by 30, 6, 11 and 2 mAbs, respectively), which correlated with mAb VH-segment usage. Some of the epitopes were partly overlapping, and they all appeared to be clustered closely together (30). In order to study antibody binding to TG2 in more detail, we used HDX-MS to identify TG2 regions with altered deuterium uptake after incubation with mAbs. Hence, mAbs targeting two non-overlapping epitopes (epitope 1 and epitope 2)
were incubated with iTG2 in the presence of Ca
2+
, and the resulting immune complexes were subjected to HDX-MS analysis. We selected two mAbs reacting with each epitope and chose the Ca 2+ -bound enzyme as antigen, since this is assumed to represent the extracellular form of TG2, which the immune system encounters.
Digestion of labeled, mAb-bound iTG2 revealed that several peptides in all four structural domains displayed altered deuterium uptake ( Fig. S4 and Table S2 ). Although the effect in most cases was small, the widespread changes indicate that we not only observe localized shielding of the epitope by the bound mAbs, but also an additional, allosteric effect on the TG2 structure. As the presence of an inhibitor in the active site presumably locks TG2 in an open conformation (Fig. S1 ), we also tested the effect of mAb binding on the effectorfree enzyme by monitoring the distribution of TG2 molecules between state A and state B (Fig. 3) . Interestingly, in the presence of epitope-1 mAbs the conformational equilibrium of 
Epitope mapping of anti-TG2 autoantibodies
Three peptides in the N-terminal domain of TG2 displayed a reduction in deuterium uptake which was specific for mAbs targeting either epitope 1 or epitope 2 and was evident at all time points (Fig. 4A and Fig. S4 ). Thus, the peptides 5-12 and 27-40 were consistently protected more by epitope-1 than epitope-2 mAbs, whereas peptide 13-26 displayed the opposite pattern. These regions therefore represented the most likely candidates for taking part in epitope 1 and 2, respectively. We previously reported that epitope 2 can be disrupted by introduction of the triple mutation R19S E153S M659S (30). This triple mutation was first described by Simon-Vecsei et al. who showed that it inhibits the binding of serum antibodies from celiac disease patients (31). Of the residues that were mutated in the previous study, Arg19 is located within the peptide we identified as an epitope-2 candidate by HDX-MS. We therefore tested the effect of the R19S mutation on mAb binding in ELISA using recombinant TG2 produced in Escherichia coli. Importantly, this protein displayed the same behavior as TG2 produced in Sf9 insect cells when analyzed by HDX-MS, indicating that the expression system does not affect the folding of the enzyme (Fig. S5) . The R19S mutant showed a dramatic loss of reactivity toward epitope-2 mAbs (Fig. 4B) , comparable to what can be observed for the triple mutant (Fig. S6A) . The binding of epitope-1 mAbs, on the other hand, was largely unaffected, indicating that the R19S mutation selectively targets epitope 2 and, to some extent, the partly overlapping epitope 3 (Fig. 4B ).
In order to confirm the location of epitope 1, we constructed TG2 variants harboring triple mutations in either of the two candidate regions identified by HDX-MS (Fig. S6B ).
Both triple mutations affected binding of epitope-1 mAbs, suggesting that both regions contribute to the epitope. To further dissect epitope 1, we assessed the binding of mAbs to TG2 containing single-amino acid mutations in the two identified regions. Glu8 in the first region and Lys30 in the second region were found to be the most important residues for binding. Mutation of each of these residues selectively abolished most of the binding for epitope-1 mAbs (Fig. 4B) .
We have previously provided evidence that epitope 1 overlaps with a binding site for fibronectin (30). The fibronectin binding site is known to be in the N-terminal domain of TG2 and could consist of several separate stretches of amino acids (32-34). In one study, Asp94 and Asp97 were shown to be important for the interaction (33). However, we observed no compromising effect of the previously described D94A and D97A mutations on the binding of epitope-1 mAbs (Fig. 4B and Fig. S6C ). Interestingly, most epitope-3 mAbs lost reactivity upon introduction of the D94A mutation (Fig. 4B) , suggesting that epitope 3, which does not overlap with the fibronecting binding site (30), is located around Asp94.
Since the epitope groups, we have assigned, reflect targeted surface areas rather than specific interactions, not all mAbs in each group showed the same loss of reactivity toward the TG2 mutants (Fig. 4B) . Thus, for some antibodies, other residues than the ones identified are expected to be important for binding. We cannot rule out that neighboring residues in the core domain are involved, but our results indicate that the main epitopes targeted by celiac disease autoantibodies are clustered in the N-terminal domain of TG2 with the four residues reported in Figure 4 collectively being important for binding most of the antibodies. The introduced mutations selectively disrupted individual epitopes and did not affect the overall conformation of TG2 as judged by non-denaturing PAGE analysis (Fig. S7A) . Interestingly, for a number of mAbs the effect of the mutations was decreased, if binding was assessed in the presence of Ca 2+ using inhibitor-bound TG2 as antigen (Fig. S7B) . Thus, Ca 
DISCUSSION
TG2 plays a central role in celiac disease, both through its enzymatic activity, which leads to gluten deamidation, and as the target of autoantibodies. Conformational changes in TG2 control the enzyme's activity and are also important for autoantibody binding. Describing the different structural states of TG2 and knowing how the enzyme conformation is regulated are therefore relevant for our understanding of celiac disease pathogenesis.
Studies performed in mice have shown that extracellular TG2 exists predominantly in a catalytically inactive form under normal conditions but can become activated through inflammation or in the presence of a reducing agent (18, 29) . The latter observation suggests that the enzyme is inactivated by oxidation in the extracellular environment. In this regard, Cys370 in TG2 has been implicated in disulfide bond formation with its neighbor Cys371 or, alternatively, with Cys230 (16, 17, 35) . Based on the disappearance of signals from the mass spectrum of TG2 following oxidation, we could confirm the formation of these disulfide bonds. In addition, we detected a previously undescribed disulfide bond between Cys524 and Cys554 (Table S2) .
The mechanism by which TG2 is inactivated by cysteine oxidation is not clearly understood, but based on the negative effect of Ca 2+ on the rate of oxidation (17, 27) , it has been proposed that structural changes induced by disulfide bond formation interferes with In the absence of effectors, we observed that the binding of TG2 by mAbs induced large-scale conformational changes in the enzyme (Fig. 3) . In the presence of Ca Recently, we showed that epitope 1 is recognized by more than half of the mAbs cloned from TG2-specific plasma cells in the celiac disease lesion (30). The majority of these mAbs used the VH5-51 gene segment, which is dominating both in the mAb panel used here (23) and in an earlier reported panel of TG2-reactive antibody fragments obtained from phage display libraries (46). The overrepresentation of VH5-51 antibodies is most likely related to the location of the epitope they recognize. Thus, a possible explanation for the VH5-51 preference is that TG2 bound by an epitope 1-targeting BCR is oriented in a way that optimizes catalytic formation of isopeptide crosslinks between BCRs on the cell surface. In this regard, it is noteworthy that the residues we have identified to be part of epitope 1 lie on an axis, which includes the active site (Fig. 4A) . The location of epitope 1 thereby predicts that the active site will face toward the BCR upon binding and implies that BCR crosslinking can happen efficiently. The location of epitope 2, on the other hand, suggests that the active site will point in a different direction with respect to the BCR upon binding. This could be a reason why epitope 2 is only recognized by 10% of the mAbs in the TG2-specific panel (30) and thus appears to be targeted less frequently than epitope 1 by plasma cells in the celiac lesion.
In conclusion, our data demonstrate the use of HDX-MS for studying conformational changes and mapping of epitopes in TG2. Binding of Ca 
MATERIALS AND METHODS
Proteins. Recombinant human TG2 was either obtained from Phadia as purified protein produced in Sf9 insect cells or expressed in E. coli and purified as previously described (17) . TG2 mutants were produced in E. coli. Mutations were introduced in the TG2 sequence using the QuickChange Site-directed Mutagenesis Kit (Stratagene) or by PCR amplification followed by subcloning into the pET-28a vector (Novagen) between the NdeI and HindIII sites. All mutations were verified by DNA sequencing (GATC Biotech). TG2-specific human mAbs were produced essentially as previously described (23, 47) . Briefly, IgG1 and Ig expression vectors containing the cloned heavy and light chain variable regions were cotransfected into HEK293 cells. Six days after transfection, antibodies were purified from the cell supernatants on Protein G sepharose (GE Healthcare). The TG2-specific mouse mAb CUB7402 was obtained from NeoMarkers. Deuterium labeling. All exchange reactions were performed at 25C in tris-buffered saline (TBS) with or without 5 mM CaCl2. Buffer made with D2O was added to 90% (v/v) to initiate labeling at a final TG2 concentration of 0.06 mg/ml. After 10, 100 and 1000 s, samples were collected and pH lowered to 2.5 by the addition of formic acid. The samples were then immediately snap-frozen in liquid nitrogen and stored at -80C until analyzed (SI Methods).
Undeuterated control samples were treated in the same way. To study effector-bound TG2, the enzyme was pre-treated at 2.6 mg/ml with 1 mM GTP or 5 mM CaCl2. The effect of antibody binding was assessed by incubating TG2 or iTG2 with a two-fold molar excess (by antigen binding sites) of TG2-specific mAbs for at least 30 min at room temperature prior to labeling. Triplicate labelings were performed and analyzed for samples which did not contain antibodies. For antibody-interaction studies, a single labeling was performed, and each sample was analyzed twice.
Non-denaturing PAGE. The preparations of TG2 and iTG2 that were used for deuterium labeling and antibody binding studies were also analyzed by non-denaturing PAGE as previously reported (12, 24) . The enzyme was either left untreated or incubated with 1 mM GTP or 5 mM CaCl2 for 30 min at room temperature prior to loading of the gel.
Electrophoresis was performed at 125 V for 75 min using ice-cold running buffer and with the gel chamber submerged in an ice bath.
ELISA assays. Wild-type or mutant TG2 produced in E. coli was coated in microtiter plates at 3 µg/ml in TBS. Incubations with mAbs were done at 37C in TBS with 0.1% (v/v) Tween20, followed by detection of bound antibody with alkaline phosphatase-conjugated rabbit anti-human IgG or goat anti-mouse IgG (Abcam). After addition of phosphatase substrate, absorbance was measured at 405 nm in a microplate reader (Thermo Scientific), and saturation binding curves were produced by non-linear regression analysis of the OD values.
In experiments where only a single mAb concentration was used, this was picked to fall within the linear range of the assay based on initial titration of each mAb. In cases where Ca -bound iTG2 was generated as described above. Closed, GTP-bound TG2 was generated by incubating the enzyme with 1 mM GTP prior to coating and keeping the GTP concentration at 50 µM during coating and antibody incubations. Oxidized iTG2 was generated prior to coating and compared to nonoxidized iTG2 in the presence of 5 mM CaCl2. . Regions where the deuterium uptake was similar in all investigated states are shown in green. -bound iTG2 was incubated in the presence or absence of TG2-specific mAbs prior to labeling. Exchange time, in seconds, is shown on the x-axis and deuterium uptake is shown on the y-axis. For clarity, uptake plots for TG2-mAb complexes, which did not result in altered deuterium uptake, are not shown. Dotted horizontal lines represent the observed deuterium uptake in a full-deuteration control. Error bars represent SD based on analytical duplicates of a single labeling. For each peptide, all shown TG2-mAb complexes were found to exhibit a different deuterium uptake than unbound TG2 in at least 2 of 3 data points, based on unpaired two-tailed t-tests (p < 0.05). (2), causing E.coli-produced TG2 to have a higher mass than the Sf9-produced enzyme. Deconvoluted mass spectra for GTPbound TG2 and Ca
2+
-bound iTG2, prior to deuteration and after 10, 100 and 1000 s exchange, are shown. The corresponding values for deuterium uptake are shown in tables and displayed in a deuterium uptake plot. The two TG2 preparations exhibit very similar deuterium uptake, indicating that there are no major differences in their folding. Note that the absolute deuterium uptake values shown here are greater than those displayed in Table S1 . This is due to these data being recorded at a later date, using an optimized analytical workflow. Values represent the mass increase in Da ± SD based on analytical duplicates of a single labeling. 
